Evidence map›Paper›PMID 39212178›Full record

Trial reportEuropean stroke journal2025

Atrial cardiopathy biomarkers and atrial fibrillation in the ARCADIA trial.

Hooman Kamel, Mitchell Sv Elkind, Richard A Kronmal, W T Longstreth, Pamela Plummer, Rebeca Aragon Garcia, Joseph P Broderick, Qi Pauls, Jordan J Elm, Fadi Nahab and 5 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European stroke journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Hooman KamelClinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-5745-0307
Mitchell Sv ElkindDepartment of Neurology, Columbia University, New York, NY, USA.
Richard A KronmalDepartments of Biostatistics, University of Washington, Seattle, WA, USA.
W T LongstrethNeurology, University of Washington, Seattle, WA, USA.
Pamela PlummerDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Rebeca Aragon GarciaDepartment of Neurology, Columbia University, New York, NY, USA.
Joseph P BroderickDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Qi PaulsDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Jordan J ElmDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Fadi NahabDepartments of Neurology and Pediatrics, Emory University, Atlanta, GA, USA.
L Scott JanisNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Marco R Di TullioDivision of Cardiology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Elsayed Z SolimanEpidemiological Cardiology Research Center, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Jeff S HealeyPopulation Health Research Institute, McMaster University, Hamilton, ON, Canada.
David L TirschwellNeurology, University of Washington, Seattle, WA, USA.

Funding

Workshop to Identify Collaborative Project(s) for the NIH StrokeNet and the Japan NEtwork for Clinical Stroke Trials (NECST)U01NS087748 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Catherine R. Dillon, Jordan J. Elm · 2014 to 2026
$14.1M
NINDS NIH HHS U01 NS087748
6 · The paper itself

Abstract

backgroundARCADIA compared apixaban to aspirin for secondary stroke prevention in patients with cryptogenic stroke and atrial cardiopathy. One possible explanation for the neutral result is that biomarkers used did not optimally identify atrial cardiopathy. We examined the relationship between biomarker levels and subsequent detection of AF, the hallmark of atrial cardiopathy.

methodsPatients were randomized if they met criteria for atrial cardiopathy, defined as P-wave terminal force >5000 μV*ms in ECG lead V

resultsOf 3745 patients who consented to screening for atrial cardiopathy, 254 were subsequently diagnosed with AF; 96 before they could be randomized and 158 after randomization. In unadjusted analyses, ln(NT-proBNP) (RR per SD, 1.99; 95% CI, 1.85-2.13), PTFV

conclusionsBiomarkers used to identify atrial cardiopathy in ARCADIA were moderately predictive of subsequent AF.

Indexed as

Atrial FibrillationNatriuretic Peptide, BrainPeptide FragmentsPyrazolesPyridonesStrokeAgedAspirinBiomarkersElectrocardiographyFemaleHeart AtriaHumansMaleMiddle AgedapixabanAspirinBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)PyrazolesPyridonesatrial cardiomyopathyatrial cardiopathyAtrial fibrillationatrial myopathystroke

Identifiers

PMID39212178
PMCPMC11569579

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.